enGene (ENGN) reported additional preliminary data from the cohort of its Phase 2 LEGEND trial of detalimogene voraplasmid in high-risk, Bacillus Calmette-Gurin-unresponsive non-muscle invasive bladder cancer patients with carcinoma in situ with or without concomitant papillary disease. The company reported an improved 6-month complete response rate under amended protocol. Data from 62 patients enrolled under the amended protocol with at least one post-baseline disease assessment demonstrated 63% complete response rate at any time.
The company said detalimogene's preliminary data to date and differentiated profile continue to support planned Biologics License Application submission in the second half of 2026.
Shares of enGene are up 62% in pre-market trade on Tuesday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.